Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas

Author(s): Francesco Bertagna*, Domenico Albano, Elisabetta Cerudelli, Maria Gazzilli, Raffaele Giubbini, Giorgio Treglia

Journal Name: Current Radiopharmaceuticals

Volume 13 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Background: Radiolabeled prostate-specific membrane antigen PSMA-based PET/CT or PET/MRI is a whole-body imaging technique currently performed for the detection of prostate cancer lesions. PSMA has been also demonstrated to be expressed by the neovasculature of many other solid tumors.

Objective: The aim of this review is to evaluate the possible diagnostic role of radiolabeled PSMA PET/CT or PET/MRI in patients with gliomas and glioblastomas, by summarizing the available literature data.

Methods: A comprehensive literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane library databases was conducted to find relevant published articles about the diagnostic performance of radiolabeled PSMA binding agents in PET/CT or PET/MRI imaging of patients with suspected gliomas or glioblastomas.

Results: Seven case reports or case series and 3 studies enrolling more than 10 patients showed that gliomas and glioblastoma are PSMA-avid tumors.

Conclusion: Radiolabeled PSMA imaging seems to be useful in analyzing glioma/glioblastoma. Further studies enrolling a wider population are needed to clarify the real clinical and diagnostic role of radiolabeled PSMA in this setting and its possible position in the diagnostic flow-chart.

Keywords: PSMA, prostate specific membrane antibodies, glioma, glioblastoma, PET, positron emission tomography.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [94 - 98]
Pages: 5
DOI: 10.2174/1874471012666191017093721

Article Metrics

PDF: 27